BPC November 27 update

PDUFA dates set for Verrica VRCA and Incyte INCY

Price and Volume Movers

Happy Thanksgiving to all readers of BioPharmCatalyst. A note that our next daily update will be on Monday December 2. Markets will be closed Thursday, while trading will close early at 1pm on Friday.

-

Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced that its New Drug Application (NDA) for VP-102, a topical therapy for the treatment of molluscum contagiosum (molluscum), has been accepted for filing by the FDA. The PDUFA date is July 13, 2020.

Incyte (NASDAQ:INCY) announced that the FDA has accepted for priority review its NDA for pemigatinib, as a treatment for patients with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements. The PDUFA date is May 30, 2020.

ObsEva SA (NASDAQ: OBSV) shares closed the session up 14% to $4.19. Phase 3 six-month primary endpoint data from its trial of Linzagolix to treat heavy menstrual bleeding (HMB) associated with uterine fibroids are due by the end of 2019.

Zosano Pharma Corporation (NASDAQ:ZSAN) shares closed up 22% to $1.86. The company announced a securities purchase agreement with institutional investors for the sale of 2,181,034 shares of its common stock at a price of $1.45 per share in a registered direct offering.

Aravive, Inc. (NASDAQ: ARAV) shares closed down 12% to $8.25 following the pricing of its public offering of 3,333,334 shares at a price of $7.50 per share for gross proceeds of $25m.

-

Major price movers (stocks priced > $1.00, volume > 50k):

Refer to the BioPharmCatalyst Biotech Stocks page for Top 10 Gainers/Losers/Unusual Volume

ADVANCERS:

ASLAN Pharmaceuticals Limited (ASLN): $2.32; +81%.

Hepion Pharmaceuticals, Inc. (HEPA): $6.27; +36%.

Ovid Therapeutics Inc. (OVID): $3.72; +19%.

Abeona Therapeutics Inc. (ABEO): $3.40; +16%.

Oramed Pharmaceuticals Inc. (ORMP): $3.74; +16%.

DECLINERS:

Baudax Bio, Inc. (BXRX): $5.60; -18%.

Benitec Biopharma Limited (BNTC): $5.39; -10%.

89bio, Inc. (ETNB): $30.12; -10%.

Verrica Pharmaceuticals Inc. (VRCA): $15.71; -10%.

Correvio Pharma Corp. (CORV): $2.12; -10%.

Pipeline updates below:

Pipeline Database Updates

Drug Stage Catalyst Market Cap

INCY – Incyte Corporation
Pemigatinib (FIGHT-202)
Cholangiocarcinoma

PDUFA priority review PDUFA date under priority review May 30, 2020.
$20.4 billion

SEEL – Seelos Therapeutics Inc.
SLS-002-102
Healthy volunteers

Phase 1 Phase 1 commencement of PK/PD dosing announced November 27, 2019. Initial data due 1Q 2020.
$28.8 million

VRCA – Verrica Pharmaceuticals Inc.
VP-102
Molluscum contagiosum

PDUFA PDUFA date July 13, 2020.
$356.7 million